Literature DB >> 8425589

Chlamydia pneumoniae infection in acute exacerbations of COPD.

F Blasi1, D Legnani, V M Lombardo, G G Negretto, E Magliano, R Pozzoli, F Chiodo, A Fasoli, L Allegra.   

Abstract

Chlamydia pneumoniae, strain TWAR, is a frequent causative agent of acute respiratory disease. We assessed the incidence and prevalence of Chlamydia pneumoniae infections in COPD. We studied, from January 1990 to May 1991, 142 out-patients with acute purulent exacerbations of chronic obstructive pulmonary disease (COPD) and 114 healthy control subjects. Oropharyngeal swab specimens were collected at each exacerbation and analysed using a high definition monoclonal indirect fluorescent antibody test for Chlamydia pneumoniae identification. Immunoglobulins G and M (IgG and IgM) fractions of antibodies to Chlamydia pneumoniae were studied by microimmunofluorescence test. Prevalence of specific IgG was 63% in COPD, and 46% in controls (Chi-squared test p = 0.007). Moreover, mean titre of IgG was significantly higher in COPD than in controls. Five patients were positive for specific IgM (> or = = 1:16), and one had a fourfold increase of IgG titre; four of these patients had been treated with ciprofloxacin 1 g.day-1 for 10 days, and two with erythromycin, 3 g.day-1 for 14 days, with remission of signs and symptoms of exacerbation. Chlamydia pneumoniae identification was always negative. Our data suggest that Chlamydia pneumoniae infection is a rather frequent event in COPD, since at least 4% of exacerbations may be associated with it.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8425589

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  35 in total

Review 1.  Chlamydial persistence: beyond the biphasic paradigm.

Authors:  Richard J Hogan; Sarah A Mathews; Sanghamitra Mukhopadhyay; James T Summersgill; Peter Timms
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

2.  Laboratory diagnosis of Chlamydia pneumoniae infections.

Authors:  R W Peeling
Journal:  Can J Infect Dis       Date:  1995-07

3.  BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS.

Authors: 
Journal:  Thorax       Date:  1997-12       Impact factor: 9.139

4.  Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms.

Authors:  F Blasi; F Denti; M Erba; R Cosentini; R Raccanelli; A Rinaldi; L Fagetti; G Esposito; U Ruberti; L Allegra
Journal:  J Clin Microbiol       Date:  1996-11       Impact factor: 5.948

Review 5.  Chlamydia pneumoniae: defining the clinical spectrum of infection requires precise laboratory diagnosis.

Authors:  S J Bourke; N F Lightfoot
Journal:  Thorax       Date:  1995-09       Impact factor: 9.139

6.  Incidence of community-acquired pneumonia caused by Chlamydia pneumoniae in Italian patients.

Authors:  F Blasi; R Cosentini; D Legnani; F Denti; L Allegra
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-09       Impact factor: 3.267

7.  Chlamydia pneumoniae seroprevalence in immunocompetent and immunocompromised populations in Milan.

Authors:  F Blasi; R Cosentini; M C Schoeller; A Lupo; L Allegra
Journal:  Thorax       Date:  1993-12       Impact factor: 9.139

8.  Chlamydia pneumoniae and chronic bronchitis: association with severity and bacterial clearance following treatment.

Authors:  F Blasi; S Damato; R Cosentini; P Tarsia; R Raccanelli; S Centanni; L Allegra
Journal:  Thorax       Date:  2002-08       Impact factor: 9.139

Review 9.  Pathogen-directed therapy in acute exacerbations of chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez
Journal:  Proc Am Thorac Soc       Date:  2007-12

Review 10.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.